Recombinant Human LRRC52 Fc Chimera Protein, CF

Catalog #: 10260-LR Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10260-LR-050

Recombinant Human LRRC52 Fc Chimera Protein SDS-PAGE

1 Image

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human LRRC52 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit neurite outgrowth of E16-E18 rat embryonic cortical neurons. Recombinant Human LRRC52 Fc Chimera, immobilized at 2.5 μg/mL on a 96 well plate, is able to significantly inhibit neurite outgrowth.

Source

Human embryonic kidney cell, HEK293-derived human LRRC52 protein

Human LRRC-52 (Ser24-Asp244) Accession # Q8N7C0	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

Q8N7C0

N-terminal Sequence
Analysis

Ser24

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

52 kDa

SDS-PAGE

60-80 kDa, under reducing conditions

Product Datasheets

10260-LR

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10260-LR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human LRRC52 Fc Chimera (Catalog # 10260-LR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-80 kDa and 120 -140 kDa, respectively.

Reconstitution Calculator

Background: LRRC52

LRRC52 (Leucine-rich repeat-containing protein 52) belongs to an extracellular leucine-rich-repeat–only (Elron) cluster, which includes five other LRRC proteins: LRRC26, LRRC38, LRRC55, LRTM1 and LRTM2 (1). Elron cluster members are type I transmembrane proteins with an extracellular domain (ECD) containing several LRR motifs and a cytoplasmic C-terminal tail with a short stretch of acidic residues (1). The mature ECD of LRRC52 is 221 amino acids (aa), containing 5 LRR motifs, and shares 76% and 78% identity with mouse and rat LRRC52, respectively. LRRC-52 is dominantly expressed in testis and skeletal muscle and is also detected in several other tissues including placenta, kidney, lung, and some glands (2, 3). LRRC52 has been identified as a testes specific SLO3 K⁺ channel accessory protein in mouse (2). LRRC52 is proposed to be essential for alkalization dependent activation of the KSper current at physiological membrane potentials and pH (2). Activation of the SLO3 channel is critical in the fertilization process and loss of function results in infertility (2, 4, 5). A second Elron cluster protein, LRRC26, was recently identified as a regulatory subunit of SLO1 BK-type K⁺ channels, suggesting a general function for the entire family (6). Based on function, LRRC52 might be a therapeutic target for male contraception (7).

References